Category Archives: Policy

Patents in Space-4

Famiya Masood, a columnist for a Pakistani newspaper, argues in a recent article that government-funded research at universities in Pakistan is not “translating into inventions that can be eventually patented.” Masood seems to believe that this is not a good … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , | Leave a comment

Patents in Space-2

Famiya Masood, a columnist for The Nation, an English-language Pakistani newspaper and law student at Northwestern University, has published an article that argues that Pakistan needs more patents from its government-funded research. Well, perhaps. But she gets Bayh-Dole wrong on … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Leave a comment

Working through an old misrepresentation of Bayh-Dole, 3

I have previously pointed out the University of Rochester’s strange policy statement with regard to commercialization. This is part of Rochester’s new and stinky. A statement currently pops up on the Rochester site that it will be down for a … Continue reading

Posted in Policy, Technology Transfer | Tagged , , | Comments Off on Working through an old misrepresentation of Bayh-Dole, 3

Bayh-Dole march-in won’t change drug prices but other things might–2

Now let’s look at alternatives to Bayh-Dole’s march-in procedures to address competition, public access, and prevention of unreasonable use, including price gouging. We will consider two within Bayh-Dole and two outside Bayh-Dole. The Bayh-Dole alternatives are: use the government license … Continue reading

Posted in Bayh-Dole, high priced drugs, Policy | Tagged , , , , | Comments Off on Bayh-Dole march-in won’t change drug prices but other things might–2

Bayh-Dole march-in won’t change drug prices but other things might–1

Folks think that somehow Bayh-Dole permits government take over of pharma patents and by doing this, somehow, the price of drugs will necessarily–magically–go down. Let’s work through this idea. Set aside for a moment that many drugs don’t do much … Continue reading

Posted in Bayh-Dole, high priced drugs, Policy | Tagged , , , , | Comments Off on Bayh-Dole march-in won’t change drug prices but other things might–1

War and Publification of Medicine Development, 3

Think of it this way, at least simplistically. You are patent counsel for the NIH in 1968. You have no control over how the NIH allocates funding, and the NIH chooses to fund lots of research and declines to fund … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Comments Off on War and Publification of Medicine Development, 3

War and Publification of Medicine Development, 2

The “war on disease” usage asserts a primary federal government role in directing the research and development of disease-directed therapies. The “war” usage asserts that the “market” for treating disease with new therapies–inventive therapies–is a governmental market, and that patents … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Comments Off on War and Publification of Medicine Development, 2

War and Publification of Medicine Development, 1

In 1944, President Roosevelt asked Vannevar Bush to respond to four questions (or, perhaps it was Vannevar Bush who arranged for President Roosevelt to ask him four questions). These questions formed the foundation for his report Science the Endless Frontier. … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , , , | Comments Off on War and Publification of Medicine Development, 1

A non-compliant Bayh-Dole written agreement at Yale-5

We are working through Yale’s “Patent Policy Acknowledgement & Agreement.” We have been looking at Paragraph 6 of the Yale patent policy to try to make sense of what inventions Yale really does assert an interest in. Paragraph 6 demands … Continue reading

Posted in Agreements, Bayh-Dole, Policy | Tagged , , , | Comments Off on A non-compliant Bayh-Dole written agreement at Yale-5

A non-compliant Bayh-Dole written agreement at Yale-4

We are working through Yale’s “Patent Policy Acknowledgement & Agreement.” Most recently we borked about employment and faculty freedom. Now let’s look at how the agreement deals with consulting. It tries to worry the problem of conflicting obligations–Yale doesn’t want … Continue reading

Posted in Agreements, Bayh-Dole, Policy | Tagged , , , , | Comments Off on A non-compliant Bayh-Dole written agreement at Yale-4